Global Genomic Testing Market By Type (Primary Erythromelalgia, Secondary Erythromelalgia), By Treatment (Drug, Surgery), By Route of Administration (Oral, Topical), By End-User (Hospitals, Homecare Settings, Specialty Clinics, Other End-Users), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2021-2031

Erythromelalgia (EM) is a rare condition that affects the feet and sometimes the hands. It is known to cause intense burning pain, severe redness, and an increase in skin temperature that can be episodic or continuous. Swelling, soreness, a deep painful aching of soft tissue, and intense burning sensations are the most common symptoms of EM. The feet are generally more affected, but symptoms can also impact the hands, face, and eyes.

EM has been classified as either primary or secondary. Primary EM relates to certain genes or is idiopathic, which means it has no recognized cause. This type of EM is more common in youngsters, particularly in their first ten years of life, but it can affect anyone at any age. Symptoms in some young individuals may begin throughout puberty.

Secondary EM is associated with other diseases or conditions, especially autoimmune diseases and myeloproliferative disorders (diseases of the blood and bone marrow). Adults are more likely to develop it, with the onset generally occurring during middle-age.

There is no one-size-fits-all treatment or cure for EM. Treating the underlying issue in secondary EM may provide relief. EM is rarely totally treatable. Doctors will focus on symptom treatment in these cases. Non-pharmacological methods should be used first, followed by topical medications, oral medications, pain rehabilitation programs, and in extreme circumstances surgery. Finding a treatment strategy that works may take some time. Surgery is considered when no other treatments provide relief.

Detailed Segmentation

The global erythromelalgia treatment market is segmented on the basis of – Type, Treatment, Route of Administration, End-User, and Region.

Based on Type

• Primary Erythromelalgia
• Secondary Erythromelalgia

Based on Treatment

• Drug
• Surgery

Based on Route of Administration

• Oral
• Topical

Based on End-User

• Hospitals
• Homecare Settings
• Specialty Clinics
• Other End-Users

Based on Regions

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Market Dynamics

One of the primary factors influencing the revenue growth of the erythromelalgia treatment market is the increase in the number of people suffering from this disease around the world. The high need for medications such as lidocaine, capsaicin, diclofenac, brimonidine, misoprostol, etc., to treat rare diseases, as well as the high demand for disease-specific innovative treatments for patients, are propelling this industry forward. This market is also influenced by financial support from respective governments to increase research efforts to create novel interventions, as well as to increase the number of mergers among key industry players.

Additionally, improvements in healthcare infrastructures, increased investments, and a greater focus on rare disorders all benefit this market for erythromelalgia treatments. Furthermore, the increased need for disease-specific new treatments would provide profitable prospects for market players.

However, the high costs of treating and diagnosing parenteral nutrition-associated cholestasis is projected to hinder market expansion opportunities. A lack of qualified expertise is also expected to pose a challenge to the erythromelalgia therapy market over the forecast period.

Key Players:

• Teva Pharmaceutical Industries Ltd.
• Biogen Inc.
• Pfizer Inc.
• Akorn Inc.
• Novartis A.G.
• Galderma S.A.
• Acorda Therapeutics Inc.
• AbbVie Pharmaceuticals
• Bausch Health Companies Inc.
• Other Key Players

For the Erythromelalgia Treatment Market research study, the following years have been considered to estimate the market size: